Yang Li, Weili Tan, Yangyini Zhang, Fang Cao, Zhisong Wu, Yang Jiao, Jie Niu
{"title":"Cardiovascular disease in idiopathic pulmonary fibrosis: a systematic review and meta-analysis of observational studies.","authors":"Yang Li, Weili Tan, Yangyini Zhang, Fang Cao, Zhisong Wu, Yang Jiao, Jie Niu","doi":"10.3389/fmed.2025.1653435","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular (CV) comorbidities can affect drug tolerability and health outcomes in patients with idiopathic pulmonary fibrosis (IPF). This systematic review and meta-analysis aimed to quantify the magnitudes of association between IPF and both overall and specific categories of CV disease.</p><p><strong>Methods: </strong>The PRISMA guidelines and PICO model were followed. We searched PubMed, Embase, Web of Science, Cochrane Library, and Chinese Biomedical Literature Service System (Sinomed) from inception to April 2025 for studies investigating CV disease in IPF patients. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). Pooled odds ratio (OR) for case-control/cross-sectional datasets and relative risk (RR) for cohort datasets were calculated using Review Manager 5.4. The <i>I</i> <sup>2</sup> test was used to evaluate the heterogeneity and the sources of heterogeneity were explored through sensitivity analyses, meta-regression, and subgroup analyses. The funnel plot and Egger's test were used to evaluate publication bias.</p><p><strong>Results: </strong>A total of 28 studies comprising 29 case-control/cross-sectional datasets and four cohort datasets were included, which indicated a positive association between IPF and CV disease (OR 2.44, 95% CI 1.84-3.24, <i>P</i> < 0.001; RR 1.44, 95% CI 1.07-1.92, <i>P</i> = 0.02). Meta-regression and maximized subgroup analyses confirmed the influence of control characteristics (<i>P</i> < 0.001), data source (<i>P</i> = 0.027), Newcastle-Ottawa Scale (NOS) score (<i>P</i> = 0.022), certainty of CV disease diagnosis (<i>P</i> = 0.027), body mass index (BMI), smoking status, and diabetes prevalence on both heterogeneity and risk estimates in the case-control/cross-sectional datasets. The OR varied across the CV disease category, with 1.14- to 2.51-fold increased risks for ischemic heart disease, thromboembolic disease, pulmonary hypertension, and other forms of heart disease.</p><p><strong>Conclusion: </strong>Idiopathic pulmonary fibrosis is significantly associated with CV disease, emphasizing the urgent need for systematic screening and risk reduction strategies in IPF patients.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/view/CRD420251013917, identifier CRD420251013917.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1653435"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497613/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1653435","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Cardiovascular (CV) comorbidities can affect drug tolerability and health outcomes in patients with idiopathic pulmonary fibrosis (IPF). This systematic review and meta-analysis aimed to quantify the magnitudes of association between IPF and both overall and specific categories of CV disease.
Methods: The PRISMA guidelines and PICO model were followed. We searched PubMed, Embase, Web of Science, Cochrane Library, and Chinese Biomedical Literature Service System (Sinomed) from inception to April 2025 for studies investigating CV disease in IPF patients. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). Pooled odds ratio (OR) for case-control/cross-sectional datasets and relative risk (RR) for cohort datasets were calculated using Review Manager 5.4. The I2 test was used to evaluate the heterogeneity and the sources of heterogeneity were explored through sensitivity analyses, meta-regression, and subgroup analyses. The funnel plot and Egger's test were used to evaluate publication bias.
Results: A total of 28 studies comprising 29 case-control/cross-sectional datasets and four cohort datasets were included, which indicated a positive association between IPF and CV disease (OR 2.44, 95% CI 1.84-3.24, P < 0.001; RR 1.44, 95% CI 1.07-1.92, P = 0.02). Meta-regression and maximized subgroup analyses confirmed the influence of control characteristics (P < 0.001), data source (P = 0.027), Newcastle-Ottawa Scale (NOS) score (P = 0.022), certainty of CV disease diagnosis (P = 0.027), body mass index (BMI), smoking status, and diabetes prevalence on both heterogeneity and risk estimates in the case-control/cross-sectional datasets. The OR varied across the CV disease category, with 1.14- to 2.51-fold increased risks for ischemic heart disease, thromboembolic disease, pulmonary hypertension, and other forms of heart disease.
Conclusion: Idiopathic pulmonary fibrosis is significantly associated with CV disease, emphasizing the urgent need for systematic screening and risk reduction strategies in IPF patients.
期刊介绍：
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
